Stockreport

VYNE Reports 2023 Fourth Quarter and Year-End Financial Results and Provides Business Update [Yahoo! Finance]

VYNE Therapeutics Inc.  (VYNE) 
PDF Anticipate commencing a Phase 2b trial for VYN201 and a Phase 1a trial for VYN202 in Q2 2024 Ended 2023 with $93.3 million of cash, cash equivalents, restricted cash [Read more]